Neurovalens Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Neurovalens Ltd - overview
Established
2013
Location
Belfast, -, UK
Primary Industry
Medical Devices & Equipment
About
Founded in 2013 and based in Belfast, UK, Neurovalens Limited operates as a medical technology company. The company was founded by its CEO, Jason McKeown, and Paul D. McGeoch. In August 2025, Neurovalens Limited raised GBP 7 million in equity and debt funding led by new investor Investment Fund for Northern Ireland, with participation from returning investors WhiteRock Capital Partners, IQ Capital, Innovation Ulster, and ACF Investors.
Other unspecified investors also participated in the round. Neurovalens develops medical devices, mainly non-invasive neurostimulation products, to treat chronic insomnia and generalized anxiety disorder. The company plans to utilize the August 2025 funding to increase sales of its existing medical devices and pursue further approvals from US regulators.
Current Investors
ACF Investors, Techstart NI, Beltrae Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Monitoring Equipment, Therapeutic Devices
Website
www.neurovalens.com/
Verticals
E-commerce, HealthTech, Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.